N/A N=50 Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 2 N=77 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Phase 2 N=34 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Phase 2 N=32 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants
N/A N=65 Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
Pleural Carcinomatosis
Primary: Pleural Carcinomatosis Identification (Compared to Standard Biopsies). Qualitative Criteria. — 8; 24; 21; 0 Participants — p=0.0003
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 2 N=65 Pembrolizumab in Treating Patients With Malignant Mesothelioma
Biphasic Mesothelioma · Epithelioid Mesothelioma · Peritoneal Malignant Mesothelioma
Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index
Phase 2 N=31 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Phase 2 N=24 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
Phase 2 N=39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
N/A N=86 ENB-GS-TBLB for the Diagnosis of PPLs
Lung Cancer
Primary: The Difference of Diagnostic Value of ENB-GS-TBLB as Compared to GS-TBLB — 34; 25; 5; 16 participants — p=0.019
Phase 4 N=121 PleuraSeal Post Market Study (Europe)
Lung Disease · Pulmonary Lobectomy
Primary: Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. — 41.9; 30.5 Percentage of participants — p=0.257
N/A N=37 Pleural Manometry for the Characterization of Spontaneous and Tension Pneumothorax
Pneumothorax · Tension Pneumothorax
Primary: Pleural Pressure (Ppl) Prior to Evacuation of Pleural Air — 7.44; -1.79 cmH2O
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 2 N=61 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Malignant Mesothelioma
Primary: Progression-Free Survival — 3.0 months
Phase 2 N=20 Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Recurrent Pleural Malignant Mesothelioma · Stage IV Pleural Mesothelioma
Primary: Progression-free Survival (PFS) — 1.8 months
Phase 2 N=30 Molecular Profiling in Lung Cancer Patients
Non-Small Cell Lung Cancer · Carcinoma
Primary: High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Phase 2 N=45 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Mesothelioma · Adenocarcinoma of Lung · Pancreatic Neoplasms
Primary: Response Assessment — 0; 0; 0; 0 Participants
Phase 3 N=400 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Malignant Pleural Mesothelioma
Primary: Overall Survival (OS) — 8.5; 8.0 months — p=0.58
Phase 3 N=605 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Mesothelioma
Primary: Overall Survival (OS) — 18.07; 14.09 Months — p=0.0020
Phase 1 N=24 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Pleural Malignant Mesothelioma
Primary: Safety/Toxicity — 0; 0 participants
Phase 2 N=30 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients Treated in Compliance With Protocol — 29 Participants
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
N/A N=119 Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
Malignant Pleural Effusion
Primary: The Proportion of Subjects Achieving Pleurodesis Without Recurrence. — 17; 12 Participants
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants